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Abstract 
The partial rebreathing method for cardiac output determination produces short periods of elevated arterial CO2 content. 
Because previous work had shown that elevated etCO2 levels increased cardiac output, mostly due to heart rate increases, 
a concern was raised that the rebreathing periods could be inducing an elevated heart rate. This could also raise the 
cardiac output (CO), since CO = (Heart Rate) X (Stroke Volume).  We studied 93 patients in the OR and the ICU who 
had undergone a total of 5142 partial rebreathing measurements by the NICO2 monitor (Novametrix Medical Systems) to 
determine whether the heart rate was raised, even if transiently, during the monitored period.  Our conclusion was that the 
rebreathing periods caused no detectable change in the heart rate.  
 
Introduction 
 
Cardiac output is a clinically important variable 
although it remains difficult to measure, since it is based 
on many interrelated factors and can vary even with 
respiration.  Information about the level of cardiac output 
describes the general health of the heart and 
cardiovascular system and can be used by physicians to 
guide care, especially in critical care situations.  Cardiac 
output is monitored clinically in about 1,000,000 patients 
each year with the bolus thermodilution technique.1   The 
thermodilution method, in which a bolus of cold saline is 
injected through a pulmonary artery (PA) catheter directly 
into the heart, is currently the most widely used and 
clinically accepted standard for measurement of cardiac 
output.2,3.  Unfortunately, the costs associated with 
placement of a PA catheter are high. Because it is 
associated with considerable morbidity and mortality, 4-6 
not all patients in whom cardiac output monitoring would 
be valuable can be monitored by thermodilution. 
 
A reliable method for measuring cardiac output non-
invasively is desirable, especially for those patients who 
are at risk for peri-operative cardiac morbidity but in 
whom the risk-benefit ratio does not justify invasive 
monitoring.  Non-invasive methods are also more 
desirable because they can be less costly and can require 
less set up time.  A number of non-invasive methods have 
been introduced for clinical use, including transthoracic 
bioimpedance, esophageal Doppler, transesophageal 
echocardiography, and NICO2 partial rebreathing.   
 
The NICO2 method is based on a version of the Fick 
equation and produces intermittent periods of elevated 
arterial CO2 content.  The difference in endtidal (or end-
expiratory) CO2 levels between the rebreathing and 
normal periods is approximately 5 mmHg.  It is during 
this period of elevated arterial CO2 levels that the 
appropriate variables for the cardiac output calculation are 
generated.  A concern was raised that since the CO2 levels 
were being elevated for the measurement, the cardiac 
output may have been raised by the measurement 
technique itself.  This concern was related to previous 
work, including that of Eger20, which stated that cardiac 
output was raised, mostly due to increased heart rate, 
when the etCO2 was raised stepwise in six-minute 
increments.   
 
To address this issue, we monitored 93 subjects in the 
OR and the ICU who underwent NICO2 non-invasive 
cardiac output monitoring to see if we could observe a 
difference in the heart rate attributable to the elevated CO2 
levels.  
 
Partial Rebreathing Non-invasive Cardiac Output 
Technology (NICO2) 
 
Our lab has developed a non-invasive CO2 
rebreathing system to measure cardiac output from the 
respiratory measurements of intubated patients.7,8   The 
NICO2 technology has been approved by the FDA and is 
commercially available for use in hospitals to monitor 
mechanically ventilated patients.  Clinical studies have 
shown that the NICO2 system performs well in intubated, 
mechanically ventilated patients. 25, 26  
 
The method is based on a principle described by 
Adolf Fick in 1870.9  Fick postulated that the quantity of a 
gas such as O2 or CO2 entering or leaving the lungs is 
equal to the quantity of the gas expelled or taken up by the 
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blood as it flows through the pulmonary capillaries and 
participates in gas exchange. (Figure 1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Circulation and gas exchange27 
 
That is, a mass balance equation can be used to describe 
how cardiac output is related to gas exchange. The 
conventional Fick technique based on O2 has long been a 
standard by which other methods of determining cardiac 
output have been evaluated: 
 
 
 
 
 
 
where  is cardiac output (liters/minute),  consumed is the 
amount of O2 consumed by tissue metabolism 
(liters/minute),  and  is the mixed venous O2 
concentration of the blood (blood flowing into the 
lungs in % volume) and CaO2 is the arterial O2 
concentration of blood flowing from the lungs (%volume). 
Unfortunately, in its original form, the Fick method is 
an invasive method requiring catheterization to determine 
the blood gas concentrations (cvO2, caO2 )and   VCO2.  The 
original Fick equation can be modified to require only 
non-invasively measured variables21-24.  This is done by 
expressing the Fick principle in terms of alveolar (A) 
instead of arterial (a) blood gas concentrations and by 
measuring CO2 elimination rather than O2 uptake: 
 
 
 
 
 
where PCBF  is the pulmonary capillary blood flow (the part 
of the cardiac output actually participating in the gas 
exchange),  VCO2 is the volume of CO2 excreted by the 
lungs per minute and CACO2 and CVCO2 are the alveolar and 
mixed venous CO2 contents, respectively.  Cardiac output 
can be calculated from   PCBF by estimating the fraction of 
cardiac output bypassing the lung (shunt fraction). 
 
The alveolar CO2 concentration can be determined 
non-invasively by monitoring the endtidal CO2 partial 
pressure in the expired gas and relating it to the blood 
concentration through a CO2 dissociation curve.  Before 
inserting the values in the Fick equation, the non-invasive 
measurements of CO2 elimination and CACO2 must be 
corrected. There are two reasons for this correction.  First, 
the lung retains some gas, even after complete expiration 
(functional residual capacity).  Second, some regions of 
the lung do not participate in the gas exchange 
(deadspace).  The NICO2 algorithm can compensate for 
these effects. 
 
To eliminate the need to know mixed venous CO2 
content, we use a partial rebreathing technique.  A 
pneumatically driven valve temporarily adds a serial dead 
space to the circuit so that the patient inhales a portion of 
the previously exhaled CO2.8,10,11 Partial rebreathing does 
not require patient cooperation and has only a small 
impact on ventilation.  The arterial CO2 content rises in 
response to this change in ventilation, and this induced 
change is used together with the amount of CO2 produced 
to calculate cardiac output. 
 
The NICO2 system estimates shunt fraction based on 
blood oxygen saturation (SpO2) data from the non-
invasive pulse oximeter and on concentration of inspired 
oxygen (FiO2).  The limited accuracy of pulse oximetry 
measurements of SpO2 (1-2%) and the steepness of the 
oxygen tension-saturation curve (especially for SpO2 > 
95%) may lead to inaccuracies in the estimates of non-
invasive shunt fraction.  In most cases, the shunt fraction 
is very small, so even a large relative error in the estimate 
of shunt fraction leads to a small error in cardiac output. 
An accuracy of up to ± 20% in the estimation of shunt 
fraction is sufficient to ensure that the error in the 
estimation of cardiac output is less than ±5%.12  
 
Clinical studies have shown that the non-invasive 
cardiac output NICO2 system performs well in intubated, 
mechanically ventilated patients, in whom regular 
breathing patterns and the good seal of the endotracheal 
tube provide optimal conditions for the NICO2 system.  A 
MEDLINE search compared the NICO2 technique with 
bioimpedance and Doppler methods.  Bias and precision 
statistics were used to determine limits of agreement with 
thermodilution (two standard deviations of the difference 
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from thermodilution / mean cardiac output) for each 
method.  The proposed NICO2 system showed better 
limits of agreement (± 28%) than either impedance (± 
37%) or Doppler(± 65%).13-19 
 
The NICO2 valve assembly  
 
The NICO2 valve assembly (Figure 2) is connected 
between the patient's breathing circuit (at the Y-piece) and 
the patient's endotracheal tube.  The NICO2 monitor 
controls the operation of the pneumatic valve by 
application of positive pressure.  In its default position, 
the pneumatic valve causes gas from the breathing circuit 
to bypass the adjustable deadspace.  When actuated, the 
pneumatic valve places the adjustable deadspace (150-450 
ml) serially in the breathing circuit between the Y piece of 
the breathing circuit and the endotracheal tube connected 
to the patient.  This causes the patient to rebreathe a 
portion of previously exhaled CO2.  The increase in 
inhaled CO2 due to rebreathing causes a reduction in the 
CO2 volume eliminated from the lung (decrease in VCO2 ) 
and a corresponding increase in alveolar and arterial CO2 
tension (increase in PACO2 and PetCO2). 
 
 
 
 
Figure 2: The NICO2 valve assembly (Novametrix 
Medical Systems) 
 
 
The Rebreathing Cycle 
 
Each NICO2 measurement cycle lasts 3 minutes, and 
is comprised of a 60 second baseline period, a 50 second 
rebreathing period, and a 70 second recovery period.  The 
resulting changes in VCO2 and PetCO2 are shown in 
Figure 3. The flow and CO2 signals are sampled at 100 Hz 
with a resolution of 0.1 L/min for flow and 0.1 mmHg for 
PCO2.  The NICO2 monitor computes and displays VCO2 
and PetCO2 data on a breath-to-breath basis.  Baseline 
values for VCO2 and PetCO2 are calculated as the average 
of a group of samples taken 27 seconds before the start of 
the rebreathing process.  During rebreathing, values for 
VCO2 and PetCO2 are calculated as the average of the 
samples taken from 25 to 50 seconds into the rebreathing 
period.  
 
The changes in PetCO2 and VCO2 are then used to 
calculate that part of the cardiac output that participates in 
gas exchange (pulmonary capillary blood flow (QPCBF)).  
The percentage of cardiac output bypassing the lung 
(shunt fraction) is determined based on Nunn's iso-shunt 
plots from the inspired O2 fraction (FiO2) values and the 
average blood oxygen saturation values (SpO2), 
determined non-invasively by a pulse oximeter.  Cardiac 
output is then calculated from QPCBF and shunt fraction. 
Figure 3:  Typical change in carbon dioxide 
elimination and end-tidal CO2 during the rebreathing 
cycle. 
 
 
 
 
 
 Methods 
 
Data Collection: 
 
The partial rebreathing cardiac monitor (NICO2, 
Novametrix Medical Systems) was used continuously on 
93 patients in the OR (n = 50) and the ICU (n = 43).  Each 
of the patients was intubated and mechanically ventilated 
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throughout the measurement period.  Patients in the OR 
were fully anesthetized under general anesthesia, while 
those in the ICU were less deeply anesthetized as they 
recovered from surgery. During each of the cases, the 
information about the etCO2 and heart rate was 
automatically stored on a laptop for later analysis.  
 
Data Analysis: 
 
Theoretically, the response of the heart rate to the 
elevated etCO2 levels could differ according to how 
deeply anesthetized the patient is, and therefore the OR 
and ICU sample groups were analyzed separately. 
 
Each recorded three minute rebreathing cycle was 
subdivided into 30 six-second intervals.  The heart rate 
and etCO2 levels recorded during the baseline interval (I0) 
were compared to levels before, during, and after the 50 
second rebreathing period.  For each cycle, differences in 
the heart rate and etCO2 were calculated for IDuring or After - 
I0 and I0 – IBefore, where ∆t (seconds) between intervals = 
TDA0 and T0B, respectively.  To account for the possibility 
of underlying trends in the heart rate, the ∆t between the 
intervals being compared was set to be equal (TDA0 = T0B). 
Thus, for each cycle, there were two resultant ∆HR and 
∆etCO2 values with respect to baseline (I0).  If the 
rebreathing were causing a change in the heart rate, one 
would expect to see a difference in HR for IDuring or After - I0 
but not for I0 – IBefore .   
 
This process of generating values for ∆HR and 
∆etCO2 was repeated for ∆t’s from 14 to 60 seconds while 
the I0 was held constant so that the entire 3 minute cycle 
period was evaluated.  This was done to check whether 
there was a delay in the response of the heart rate to 
elevated CO2 levels such that it occurred after rebreathing 
was completed. 
 
 To test whether the differences measured were 
significantly different, a second part of the evaluation was 
necessary.  The same data was again evaluated with the 
procedure outlined above, but all intervals occurred 
during the baseline (non-rebreathing) period.  This set of 
data was considered to be the control data which describes 
the inherent variation in the respiratory signals and heart 
rate during non-rebreathing periods.  The student’s t-test 
was used to determine whether the sample and control 
values were significantly different from one another for 
each set of ∆t’s where TDA0sample = TDA0control  and T0Bsample 
= T0Bcontrol.  Standard deviations, averages, and averages 
of differences were also calculated. 
 
Results 
 
A total of 5142 measurement cycles  from 50 patients 
in the OR and 43 patients in the ICU were examined.  In 
the OR, an average increase in etCO2 of 5.1 mmHg had a 
corresponding average decrease in the heart rate of 0.24 
beats/min.  The standard deviations were 3.0 mmHg for 
etCO2 and 5.5 beats/min for heart rate.   The sample and 
control groups were found to be statistically different (p< 
0.05) from each other for etCO2 but not for HR. 
 
In the ICU, and average increase of 7.8 mmHg in 
etCO2 levels corresponded to a heart rate decrease of 0.34 
beats/min, with standard deviations of 3.1 mmHg and 6.8 
beats/min, respectively. 
 
Discussion 
 
We compared baseline heart rates to rebreathing time 
periods and other periods throughout the cycle to examine 
whether the heart rate was changed, but did not find 
statistically significant differences (at a 0.05 significance 
level). The variability in the heart rate was so large that 
the standard deviation was much larger than any observed 
differences in heart rate.  This is an important point 
clinically, as some doctors are under the impression that 
elevated etCO2 levels produced by the NICO2 could 
increase HR. 
 
We observed that the heart rate actually decreased by 
less than one beat per minute, but this value was so small 
compared to the variability that there is really no change. 
This is in contradiction to the results found in the 
literature.  One explanation for this contradiction could be 
that the etCO2 was elevated in our method for only 50 
seconds, while in the literature, etCO2 was elevated for six 
minutes.  During the shorter time period of rebreathing 
used by NICO2 we did not observe a difference in heart 
rate caused by increases in etCO2 and have concluded that 
the concerns related to the possible increases in heart rate 
do not affect NICO2 performance. 
 
It was somewhat surprising that the HR did not 
change in the ICU patients.  This could have been due to 
remaining effects of  anesthesia or because there is really 
no induced change during a short partial rebreathing 
period.  This issue should be tested further in 
spontaneously breathing, awake subjects. 
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